PMID- 35687706
OWN - NLM
STAT- MEDLINE
DCOM- 20220909
LR  - 20220909
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 28
IP  - 6
DP  - 2022 Sep
TI  - Analysis of the Clinical Efficacy of Conservative Treatment for an Unruptured 
      Cornual Pregnancy.
PG  - 118-123
LID - AT7127 [pii]
AB  - CONTEXT: Early diagnosis and early treatment of cornual pregnancy are very 
      important. Conservative treatment before rupture can greatly reduce the patient's 
      trauma. It's very important to choose a treatment method for cornual pregnancy 
      with a high level of effectiveness, few adverse reactions, and no effects on 
      fertility. OBJECTIVE: The study intended to compare the clinical efficacy of 
      different treatments for unruptured cornual pregnancy to find a safe, effective, 
      minimally invasive treatment for unruptured cornual pregnancy that has few side 
      effects and doesn't affect fertility. DESIGN: The research team retrospectively 
      collected the clinical data of patients to analyze the benefits of treatments for 
      cornual pregnancy. SETTING: The study took place in the Department of Obstetrics 
      and Gynecology at the Wuhan Third Hospital in Wuhan, Hubei Province, China. 
      PARTICIPANTS: Participants were 61 patients with an unruptured cornual pregnancy 
      who had been admitted to the hospital between September 2002 and May 2012. 
      INTERVENTION: Participants were divided into four groups according to the 
      treatment they received: (1) 20 patients who had been orally administered 
      mifepristone combined with misoprostol and received uterine curettage were 
      included in the drug abortion + curettage group (D group); (2) 16 patients who 
      had received ultrasound-guided uterine aspiration were included in the uterine 
      aspiration group (U group); (3) 15 patients who had received methotrexate (MTX) 
      chemotherapy were included in the chemotherapy group (C group); and (4) 10 
      patients who had received ultrasound-guided hysteroscope operation were included 
      in the hysteroscope operation group (H group). OUTCOME MEASURES: Adverse 
      reactions and the decrease in participants' blood beta-HCG were recorded in detail. 
      The participants were followed up for two months. RESULTS: Of the 61 
      participants, 12 underwent surgery after failed conservative treatment, one in 
      the D group, four in the U group, three in the C group, and four in the H group. 
      No significant difference existed in the baseline data among the four groups. The 
      decline rates of beta-HCG at seven days after treatment and the treatment success 
      rates of participants in the D group were significantly higher than those in the 
      U group, the C group, and the H group (all P < .05). The time at which the beta-HCG 
      turned negative and the average hospital stays weren't significantly different 
      among the four groups. CONCLUSIONS: The current study found that oral 
      administration of mifepristone, combined with misoprostol, plus uterine curettage 
      was superior to the other three methods in treatment of unruptured cornual 
      pregnancy. The drug abortion + curettage treatment was found to be a safe, 
      effective, minimally invasive treatment for unruptured cornual pregnancy, which 
      has few side effects and doesn't affect fertility.
FAU - Li, Jing
AU  - Li J
FAU - Wang, Renxiao
AU  - Wang R
FAU - Huang, Hongli
AU  - Huang H
FAU - Yang, Yi
AU  - Yang Y
FAU - Lu, Jingquan
AU  - Lu J
FAU - Liu, Heyu
AU  - Liu H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 0E43V0BB57 (Misoprostol)
RN  - 320T6RNW1F (Mifepristone)
SB  - IM
MH  - Conservative Treatment
MH  - Female
MH  - Humans
MH  - Mifepristone/therapeutic use
MH  - *Misoprostol
MH  - Pregnancy
MH  - *Pregnancy, Cornual
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2022/06/11 06:00
MHDA- 2022/09/11 06:00
CRDT- 2022/06/10 14:12
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/09/11 06:00 [medline]
PHST- 2022/06/10 14:12 [entrez]
AID - AT7127 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2022 Sep;28(6):118-123.